StockNews.com Downgrades LeMaitre Vascular (NASDAQ:LMAT) to Hold

StockNews.com downgraded shares of LeMaitre Vascular (NASDAQ:LMAT - Free Report) from a buy rating to a hold rating in a report issued on Friday.

LMAT has been the subject of several other research reports. Oppenheimer restated an "outperform" rating and set a $93.00 target price (up previously from $90.00) on shares of LeMaitre Vascular in a research report on Friday, November 1st. JMP Securities upped their price objective on LeMaitre Vascular from $77.00 to $100.00 and gave the company a "market outperform" rating in a research report on Tuesday, August 20th. Barrington Research increased their target price on LeMaitre Vascular from $92.00 to $93.00 and gave the stock an "outperform" rating in a research note on Friday, November 1st. Finally, Cantor Fitzgerald started coverage on shares of LeMaitre Vascular in a research report on Tuesday, October 15th. They issued a "neutral" rating and a $96.00 price objective for the company. Three research analysts have rated the stock with a hold rating, six have given a buy rating and one has issued a strong buy rating to the company. According to data from MarketBeat, the stock currently has an average rating of "Moderate Buy" and an average price target of $94.57.

LeMaitre Vascular Price Performance

Shares of NASDAQ:LMAT traded up $0.41 during trading on Friday, hitting $100.69. The company had a trading volume of 183,716 shares, compared to its average volume of 124,557. The stock has a market cap of $2.26 billion, a price-to-earnings ratio of 55.02, a price-to-earnings-growth ratio of 2.47 and a beta of 0.93. The company has a fifty day simple moving average of $97.47 and a two-hundred day simple moving average of $89.33. LeMaitre Vascular has a one year low of $52.88 and a one year high of $109.58.

LeMaitre Vascular (NASDAQ:LMAT - Get Free Report) last posted its quarterly earnings data on Thursday, October 31st. The medical instruments supplier reported $0.49 earnings per share for the quarter, beating analysts' consensus estimates of $0.44 by $0.05. The business had revenue of $54.82 million for the quarter, compared to analysts' expectations of $53.50 million. LeMaitre Vascular had a net margin of 19.40% and a return on equity of 13.15%. The business's revenue was up 15.6% compared to the same quarter last year. During the same quarter in the previous year, the business posted $0.33 earnings per share. On average, equities research analysts anticipate that LeMaitre Vascular will post 1.94 earnings per share for the current year.

LeMaitre Vascular Announces Dividend

The company also recently disclosed a quarterly dividend, which was paid on Thursday, December 5th. Investors of record on Thursday, November 21st were paid a dividend of $0.16 per share. The ex-dividend date was Thursday, November 21st. This represents a $0.64 annualized dividend and a dividend yield of 0.64%. LeMaitre Vascular's dividend payout ratio (DPR) is presently 34.97%.

Insider Buying and Selling at LeMaitre Vascular

In related news, Director Bridget A. Ross sold 3,750 shares of LeMaitre Vascular stock in a transaction that occurred on Friday, November 15th. The shares were sold at an average price of $101.47, for a total value of $380,512.50. Following the completion of the sale, the director now directly owns 2,278 shares in the company, valued at $231,148.66. This trade represents a 62.21 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. 10.79% of the stock is owned by insiders.

Institutional Investors Weigh In On LeMaitre Vascular

Large investors have recently made changes to their positions in the stock. SG Americas Securities LLC acquired a new stake in LeMaitre Vascular during the second quarter worth about $177,000. Hennion & Walsh Asset Management Inc. boosted its holdings in LeMaitre Vascular by 62.2% in the 2nd quarter. Hennion & Walsh Asset Management Inc. now owns 10,289 shares of the medical instruments supplier's stock worth $847,000 after buying an additional 3,947 shares during the last quarter. Fifth Third Bancorp raised its holdings in shares of LeMaitre Vascular by 6.6% during the second quarter. Fifth Third Bancorp now owns 10,888 shares of the medical instruments supplier's stock valued at $896,000 after acquiring an additional 678 shares during the last quarter. Louisiana State Employees Retirement System boosted its stake in shares of LeMaitre Vascular by 3.1% in the second quarter. Louisiana State Employees Retirement System now owns 10,100 shares of the medical instruments supplier's stock worth $831,000 after acquiring an additional 300 shares during the last quarter. Finally, West Oak Capital LLC purchased a new stake in shares of LeMaitre Vascular during the second quarter worth approximately $58,000. 84.64% of the stock is owned by hedge funds and other institutional investors.

LeMaitre Vascular Company Profile

LeMaitre Vascular, Inc develops, manufactures, and markets medical devices and implants used in the field of vascular surgery worldwide. It offers human cadaver tissue cryopreservation services; angioscope, a fiberoptic catheter used for viewing the lumen of a blood vessel; embolectomy catheters to remove blood clots from arteries; thrombectomy catheters for removing thrombi in the venous system; occlusion catheters that temporarily occlude the blood flow; and perfusion catheters to perfuse the blood and other fluids into the vasculature.